Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Chronic Heart Failure
Authors: Victor C. Lee, David C. Rhew, Glenn D. Braunstein
Journal: Annals of Internal Medicine (2005)

Letters1 March 2005Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Chronic Heart FailureVictor C. Lee, MD, David C. Rhew, MD, and Glenn D. Braunstein, MDVictor C. Lee, MDFrom Zynx Health Incorporated, Los Angeles, CA 90024, and Cedars-Sinai Health System, Los Angeles, CA 90048.Search for more papers by this author, David C. Rhew, MDFrom Zynx Health Incorporated, Los Angeles, CA 90024, and Cedars-Sinai Health System, Los Angeles, CA 90048.Search for more papers by this author, and Glenn D. Braunstein, MDFrom Zynx Health Incorporated, Los Angeles, CA 90024, and Cedars-Sinai Health System, Los Angeles, CA 90048.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-142-5-200503010-00020 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We are pleased to hear that CMS, JCAHO, and several other collaborating organizations concur that ARBs should no longer be excluded from the CMS and JCAHO quality indicators for heart failure and acute MI. The implementation of the revised heart failure and acute MI measures in 2 phases makes practical sense as described by McClellan and colleagues as well as on the JCAHO Web site (1).We respectfully disagree with the statement of Drs. Peeters and Tsikouris that the current quality indicators should remain unchanged. A previous meta-analysis by Jong and colleagues (2) showed no statistically significant difference ...References1. Joint Commission on Accreditation of Healthcare Organizations. Change in ACEI for LVSD Measures (HF-3, AMI-3): Incorporation of ARBs. 15 November 2004. Accessed at www.jcaho.org/pms/core+measures/changeinaceiforlvsdmeasuresincorparbs.pdf on 23 December 2004. Google Scholar2. Jong P, Demers C, McKelvie RS, Liu PP. Angiotensin receptor blockers in heart failure: meta-analysis of randomized, controlled trials. J Am Coll Cardiol. 2002;39:463-70. [PMID: 11823085] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Victor C. Lee, MD; David C. Rhew, MD; Glenn D. Braunstein, MDAffiliations: From Zynx Health Incorporated, Los Angeles, CA 90024, and Cedars-Sinai Health System, Los Angeles, CA 90048. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoMeta-Analysis: Angiotensin-Receptor Blockers in Chronic Heart Failure and High-Risk Acute Myocardial Infarction Victor C. Lee , David C. Rhew , Michelle Dylan , Enkhe Badamgarav , Glenn D. Braunstein , and Scott R. Weingarten Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Chronic Heart Failure Mark B. McClellan , Jerod M. Loeb , Carolyn M. Clancy , Gary S. Francis , Alice K. Jacobs , Kenneth W. Kizer , Margaret E. O'Kane , and Michael J. Wolk Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Chronic Heart Failure Michael J. Peeters and James P. Tsikouris Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Chronic Heart Failure Loren D. Regier and Brent Jensen Metrics 1 March 2005Volume 142, Issue 5Page: 388-389KeywordsACE inhibitorsAngiotensin converting enzyme inhibitorAngiotensin receptor blockerCongestive heart failureHeart failureHospitalizationsMortalityQuality indicatorsStatistical data ePublished: 1 March 2005 Issue Published: 1 March 2005 Copyright & PermissionsCopyright © 2005 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...